Searched for
SEMAGLUTIDE PRICING
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Defence, power and import substitution are emerging as long-term winners: Prateek AgarwalIndian corporate earnings are meeting expectations, but market sentiment is subdued due to broader economic concerns, not company performan...
- Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block dealShares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Be stock-specific, look for bargains: Daljeet Kohli on Nifty at 24,000 and top sector picksMarket expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
Load More
